Completed PHASE3 INTERVENTIONAL 2-arm NCT01854632

Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal

A Randomized, Double-Blind, Placebo-Controlled Trial of the Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal

Sponsor: Centers for Disease Control and Prevention

Conditions Influenza

Interventions Matched placebo SIIL Live Attenuated Influenza Vaccine

Updated 7 times since 2017 Last updated: Jun 1, 2015 Started: May 31, 2013 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01854632, this PHASE3 trial focuses on Influenza and remains completed. Sponsored by Centers for Disease Control and Prevention, it has been updated 7 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centers for Disease Control and Prevention
Institut Pasteur de Dakar
Institut de Recherche pour le Developpement
PATH

Data source: PATH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Niakhar, Senegal